Comparing the current results to its competitors, Citius Pharmaceuticals Inc reported Revenue increase in the 3 quarter 2026 by 0 % year on year. The revenue growth was below Citius Pharmaceuticals Inc 's competitors' average revenue growth of 6.34 %, achieved in the same quarter.
Citius Pharmaceuticals Inc , slower than the average decrease reported by the company's competitors of -12.67 %. recorded a net loss and most of the company's competitors saw a decline in earnings by -12.67 %
Citius Pharmaceuticals Inc 's Comment on Competition and Industry Peers
Citius Pharmaceuticals operates in the pharmaceutical industry, which is characterized by significant competition and regulatory oversight. The company faces competition from larger pharmaceutical and biotechnology firms, as well as academic institutions and government agencies. Citius Pharmaceuticals holds an exclusive license for the product LYMPHIR (E7777), acquired from Dr. Reddy's, who had previously licensed it from Eisai. Under this agreement, Dr. Reddy's has agreed not to compete with Citius Pharmaceuticals in developing products containing compounds in LYMPHIR within the licensed territory for a specified period. Additionally, Brooklyn assumed the NoveCite license and later changed its name to Eterna Therapeutics Inc. The company acknowledges the existence of several approved targeted therapeutics for patients, indicating competition in that therapeutic area.
Publicly Traded Peers of Citius Pharmaceuticals Inc
Ocular Therapeutix Inc Share Performance
+6.49%
30 Days
Ocular Therapeutix Inc
Profile
Ocular Therapeutix Inc is a biopharmaceutical company that focuses on developing and commercializing innovative therapies for diseases and conditions of the eye. They utilize their proprietary hydrogel technology to design and manufacture sustained-release treatments that can be administered during routine eye exams and eliminate the need for patient compliance with eye drops.
Medicinova Inc operates under a biopharmaceutical business model, primarily focused on the development and commercialization of innovative therapeutics. They strive to identify promising drug candidates with the potential to address unmet medical needs and advance them through clinical trials. By leveraging their research capabilities, strategic partnerships, and licensing opportunities, Medicinova Inc aims to bring these novel treatments to market and improve patient outcomes.
Ocugen Inc's business model is focused on the development and commercialization of innovative gene therapies to treat rare and underserved ocular diseases, with a particular emphasis on underserved patient populations. They aim to leverage their expertise in gene therapy and partnerships to advance novel treatments and bring them to market, ultimately improving the lives of patients in need.
Puma Biotechnology Inc operates as a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for the treatment of cancer. Their business model revolves around identifying promising preclinical and clinical drug candidates, conducting rigorous research and development, and seeking regulatory approval for their products. Puma Biotechnology Inc strives to effectively market and distribute their approved therapeutics to provide patients with potentially life-saving treatment options.
Teva Pharmaceutical Industries Limited is a multinational pharmaceutical company that focuses on the development, production, and marketing of generic and specialty medicines. They aim to provide affordable and accessible healthcare solutions to patients worldwide.
Sources:
Citius Pharmaceuticals Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Citius Pharmaceuticals Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
